AU2023210771A1 - Oncolytic virus and use thereof - Google Patents

Oncolytic virus and use thereof Download PDF

Info

Publication number
AU2023210771A1
AU2023210771A1 AU2023210771A AU2023210771A AU2023210771A1 AU 2023210771 A1 AU2023210771 A1 AU 2023210771A1 AU 2023210771 A AU2023210771 A AU 2023210771A AU 2023210771 A AU2023210771 A AU 2023210771A AU 2023210771 A1 AU2023210771 A1 AU 2023210771A1
Authority
AU
Australia
Prior art keywords
protein
amino acid
mutation
oncolytic virus
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023210771A
Other languages
English (en)
Inventor
Liang Ma
Ting TIAN
Fan Zhang
Guoqing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joint Biosciences SH Ltd
Original Assignee
Joint Biosciences SH Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Biosciences SH Ltd filed Critical Joint Biosciences SH Ltd
Publication of AU2023210771A1 publication Critical patent/AU2023210771A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2023210771A 2022-01-26 2023-01-09 Oncolytic virus and use thereof Pending AU2023210771A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210094869.1 2022-01-26
CN202210094869.1A CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
PCT/CN2023/071375 WO2023143023A1 (zh) 2022-01-26 2023-01-09 溶瘤病毒及其应用

Publications (1)

Publication Number Publication Date
AU2023210771A1 true AU2023210771A1 (en) 2024-08-15

Family

ID=81673943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023210771A Pending AU2023210771A1 (en) 2022-01-26 2023-01-09 Oncolytic virus and use thereof

Country Status (8)

Country Link
US (1) US20240424040A1 (https=)
EP (1) EP4471132A4 (https=)
JP (1) JP2025503188A (https=)
KR (1) KR20240137069A (https=)
CN (6) CN119709650A (https=)
AU (1) AU2023210771A1 (https=)
CA (1) CA3243385A1 (https=)
WO (1) WO2023143023A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119709650A (zh) * 2022-01-26 2025-03-28 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用
CN116350759A (zh) * 2023-03-30 2023-06-30 上海荣瑞医药科技有限公司 溶瘤病毒疫苗和免疫细胞联合治疗肿瘤的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1769433B (zh) * 2004-11-04 2011-03-16 张庆勇 重组水疱性口炎病毒及其应用
RU2010124788A (ru) * 2007-12-21 2012-01-27 Ваейт ЭлЭлСи (US) Генетически модифицированный ослабленный вирус везикулярного стоматита, композиции и способы их применения
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
CN105087645A (zh) * 2015-08-04 2015-11-25 上海交通大学 M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用
EP3246410A1 (en) * 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
CN110305198B (zh) * 2018-03-27 2021-01-29 睿丰康生物医药科技(浙江)有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
CN110819657B (zh) * 2018-08-10 2021-11-19 睿丰康生物医药科技(浙江)有限公司 一种减毒棒状病毒的制备方法及应用
TWI894135B (zh) * 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
CN111467489B (zh) * 2020-05-12 2022-06-03 上海荣瑞医药科技有限公司 一种治疗肿瘤的药物
CN111286493B (zh) * 2020-05-12 2020-10-27 上海荣瑞医药科技有限公司 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
CN119709650A (zh) * 2022-01-26 2025-03-28 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用

Also Published As

Publication number Publication date
JP2025503188A (ja) 2025-01-30
CN119709650A (zh) 2025-03-28
US20240424040A1 (en) 2024-12-26
CN119709652A (zh) 2025-03-28
CN114540316B (zh) 2025-01-03
CN119709651A (zh) 2025-03-28
CN119736261A (zh) 2025-04-01
CA3243385A1 (en) 2025-06-17
KR20240137069A (ko) 2024-09-19
CN119709649A (zh) 2025-03-28
EP4471132A4 (en) 2026-02-25
EP4471132A1 (en) 2024-12-04
WO2023143023A1 (zh) 2023-08-03
CN114540316A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
AU2023210771A1 (en) Oncolytic virus and use thereof
EP3153577B1 (en) Method for modification of heat resistance of newcastle disease virus and use thereof
Niu et al. Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model
JP2025503188A5 (https=)
EP4545634A1 (en) Recombinant oncolytic virus and use thereof
US11793844B2 (en) Virus for treatment of tumor
US11732012B2 (en) Attenuated strains of oncolytic rhabdovirus and uses thereof in tumor treatment
JP6944692B2 (ja) ボルナウイルスベクター及びその利用
AU2022312026B2 (en) Oncolytic virus and use thereof
WO2020239118A1 (zh) M1病毒变异体及其应用
KR101653401B1 (ko) 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄ
CA3073770A1 (en) An echovirus for treatment of tumors
HK40105653A (en) Oncolytic virus and use thereof
van den Hengel et al. Genetic modification in mammalian orthoreoviruses
Lee et al. Reduced pathogenicity of velogenic NDV strain AF22420-I via site-directed mutagenesis of V gene
CA3070628C (en) Enterovirus d68 (ev-d68) for treatment of tumor
CN113817729A (zh) 一种抑制新型冠状病毒（CoV19）的siRNA及其组合物和应用
Armeanu et al. 92. Further Attenuation of Gene (s)-Deleted Sendai Virus Vectors: Modification of Transcription and Replication Caused Weakened Cytotoxicity
CN102618541A (zh) 用于治疗呼吸道病毒感染的组合物及其用途